Alector Prices 36.6 Million Shares At $2.05, Adding 24.7% To Its Share Count

The biotech set a $75.0 million gross offering price above Thursday's last reported sale of $1.91, with Morgan Stanley and BTIG leading.

Share
Alector Prices 36.6 Million Shares At $2.05, Adding 24.7% To Its Share Count

Alector priced a follow-on sale of 36,600,000 shares of common stock at $2.05 each, for gross proceeds of $75,030,000, according to a prospectus supplement dated Friday. The new shares would equal 24.7% of the 148,256,805 shares outstanding after the offering.

What the prospectus supplement says

The $2.05 price compares with a last reported sale price of $1.91 on Thursday, October 15, on the Nasdaq Global Select Market, which makes it 7.3% higher. At Friday's close the shares stood at $1.84, per market data.

Underwriting discounts and commissions come to $0.123 a share, or $4,501,800 in total, leaving $70,528,200 before expenses. After expenses, the company estimates net proceeds of about $70.2 million.

Alector earmarks the cash "for general corporate purposes," a category it says could cover pipeline R&D and manufacturing, working capital, capex, overhead, or buying into complementary products, technologies or businesses. Management will have broad discretion over the timing and use, and pending use the cash will go into short-term, investment-grade, interest-bearing instruments.

Morgan Stanley and BTIG are the joint active bookrunners. Delivery of the shares is expected on or about Monday, October 19.

What it changes for holders

The share count is based on 111,656,805 shares outstanding as of June 30, 2026, before the new shares. That count excludes 10,043,385 options at a weighted-average exercise price of $11.38, plus further options, restricted stock units and reserved plan shares listed in the supplement.

New buyers face immediate dilution of $1.64 per share in net tangible book value, based on the $2.05 price. The company's net tangible book value at June 30 was negative: about $(9.97) million, or $(0.09) per share. After the offering it would be about $60.3 million, or about $0.41 per share, a $0.50 per-share increase for existing holders.

The supplement also warns that future financings could bring more dilution, and that the company may sell stock later at a lower price.

The at-the-market agreement and lock-up

The supplement separately discloses a May 7, 2026 sales agreement with TD Securities under which shares with an aggregate offering price of up to $125.0 million remain available. Alector sold no shares under it between June 30 and the supplement date. It has agreed to make no sales under it until the 30-day lock-up on the company expires or is waived. That capacity is not included in the share count above.

The at-the-market capacity of up to $125.0 million stays shut until the company's 30-day lock-up expires or is waived.

Sources

More on Alector

All Alector (ALEC) coverage →